Celgene Corporation
http://www.celgene.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celgene Corporation
After Ups and Downs, Industry Attempts To Normalize In Q3
After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.
JPM 2021: Conformis Announces ACS Knee For 2H 2021, Integra Weathers Pandemic
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the final day of the meeting.
Migraine & Hepatitis B Prevention Products Among New EU Filings
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Another EU Filing Targets Burgeoning NMOSD Market
Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Abraxis BioScience, Inc.
- AbVitro, Inc.
- Acetylon Pharmaceuticals, Inc.
- Avila Therapeutics, Inc.
- Delinia, Inc.
- EngMab AG
- Gloucester Pharmaceuticals, Inc.
- Impact Biomedicines, Inc.
- Juno Therapeutics, Inc.
- Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
- JW Biotechnology (Shanghai) Co., Ltd
- Pharmion Corporation
- Quanticel Pharmaceuticals, Inc.
- Receptos, Inc.
- RedoxTherapies, Inc.
- X-BODY, Inc.